CSIMarket Company Name, Ticker, Suppliers, else..
 
Bioage Labs Inc   (NASDAQ: BIOA)
 
Price: $8.4500 $-0.20 -2.312%
Day's High: $8.885000228881836 Week Perf: -11.89 %
Day's Low: $ 8.41 30 Day Perf: -19.37 %
Volume (M): 145,165 52 Wk High: $ 25.95
Volume (M$): $ 0 52 Wk Avg: $14.80
Open: $8.71 52 Wk Low: $4.68



 Market Capitalization (Millions $) 379
 Shares Outstanding (Millions) 45
 Employees 62
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -94
 Cash Flow (TTM) (Millions $) 21
 Capital Exp. (TTM) (Millions $) 0

Business Description


BioAmber Inc. is a renewable chemistry company that produces sustainable chemicals and materials from agricultural feedstocks. They specialize in the production of bio-based succinic acid, a key building block for many products. Their innovative technology allows them to convert sugars from crops like corn into high-quality chemicals and materials. These sustainable alternatives have a significantly lower carbon footprint compared to their petrochemical counterparts. BioAmber Inc. is committed to creating a greener future by providing renewable solutions for a wide range of industries.


   Company Address: 5885 Hollis St Emeryville, CA 94608 CA
   Company Phone Number: 806-1445   Stock Exchange / Ticker: NASDAQ BIOA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

BioAge Labs, Inc. Faces Class Action Lawsuit Following Stock Performance Decline

Published Mon, Feb 24 2025 5:33 PM UTC

In recent developments, BioAge Labs, Inc. (NASDAQ: BIOA) has become the subject of a class action securities lawsuit. Law firm Levi & Korsinsky, LLP is leading this initiative, calling upon investors who may have incurred financial losses associated with their investments in BioAge to join the suit.BioAge Labs, a biotechnology company specializing in the development of thera...
Announcement

Rosen Law Firm Urges BioAge Labs Investors to Seek Legal Counsel Before March 10 Deadline,

Published Sat, Jan 25 2025 3:22 PM UTC

Investors Urged to Act Ahead of Key Deadline in BioAge Labs Class Action Lawsuit New York, Jan. 25, 2025 The Rosen Law Firm, a respected global advocate for investor rights, has issued a reminder to investors of BioAge Labs, Inc. (NASDAQ: BIOA) who purchased shares pursuant to the company s initial public offering (IPO) on September 26, 2024. Investors are encouraged to ...
Partnership

Innovative Collaborations in Biopharmaceuticals Unveiling the Future of Age-Related Disease Therapies and Revenue G...

Published Sat, Dec 28 2024 3:40 AM UTC

In recent years, the biopharmaceutical landscape has experienced significant transformations driven by innovative collaborations and strategic partnerships aimed at addressing pressing health challenges, particularly those related to aging. A paramount instance of this trend is highlighted by the multi-year collaboration between BioAge Labs and Novartis. This partnership is ...
Management Announcement

Biotech Breakthroughs vs. Financial Fumbles: The Diverging Paths of BioAge Labs and BioAmber Inc.

Published Mon, Nov 4 2024 2:00 PM UTC

Navigating Biotech Breakthroughs Amidst Financial Turbulence: BioAge Labs and BioAmber Inc. In an era where the battle against obesity is fought on multiple fronts, BioAge Labs stands at the intersection of innovation and public health. The biotech company is preparing to present preclinical data for its APJ agonist, Azelaprag, during ObesityWeek 2024. This announcement ar...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 36.59
Price to Sales (Expected) -
Price to Book 1.01
PEG (TTM) -

Financial Strength Current
Quick Ratio 16.59
Working Capital Ratio 17.32
Leverage Ratio (MRQ) 0.06
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.38 $
Revenues (TTM) 0.23 $
Cash Flow (TTM) 0.48 $
Cash 7.11 $
Book Value 8.36 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 167,016
Net Income per Employee (TTM) -1,523,613
Receivable Turnover Ratio (TTM) 15.82
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.03

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -1196.78 %
Net Margin (MRQ) -1064.75 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Bioage Labs Inc's Segments
Member    213.1 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.